My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

53.66 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 686
Open 53.66
Bid (Size) 53.40 (5)
Ask (Size) 53.69 (5)
Prev. Close 53.66
Today's Range 53.66 - 53.66
52wk Range 21.34 - 58.40
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
+91.1%
+91.1%
1 Month
+26.0%
+26.0%
3 Month
-1.2%
-1.2%
6 Month
+42.6%
+42.6%
1 Year
+72.8%
+72.8%

More News

Read More
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk
Via Investor's Business Daily
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Wall Street Pulls Back as Earnings Season Kicks Off; PepsiCo, Delta, and Costco Defy the Trend
Via Chartmill
Topics Stocks
Why Akero Therapeutics Stock Trounced the Market on Thursday
Via The Motley Fool
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today
Via Stocktwits
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates AKRO, CCRD, AL, PBBK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE - AL)
From Brodsky & Smith LLC
Via GlobeNewswire
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Via Benzinga
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Dow Futures Inch Up As Wall Street Awaits Jerome Powell’s Speech: TSLA, NVO, DAL, PEP Among Stocks To Watch
Via Stocktwits
Topics Economy Stocks
What’s Driving The Super Rally In Akero Shares On Thursday Morning?
Via Stocktwits
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism
Via Chartmill
Akero (AKRO) Q2 Loss Narrows 6%
Via The Motley Fool
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Akero Therapeutics, Inc. - Common Stock publicly traded?
Yes, Akero Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Akero Therapeutics, Inc. - Common Stock trade on?
Akero Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Akero Therapeutics, Inc. - Common Stock?
The ticker symbol for Akero Therapeutics, Inc. - Common Stock is AKRO on the Nasdaq Stock Market
What is the current price of Akero Therapeutics, Inc. - Common Stock?
The current price of Akero Therapeutics, Inc. - Common Stock is 53.66
When was Akero Therapeutics, Inc. - Common Stock last traded?
The last trade of Akero Therapeutics, Inc. - Common Stock was at 10/16/25 04:00 PM ET
What is the market capitalization of Akero Therapeutics, Inc. - Common Stock?
The market capitalization of Akero Therapeutics, Inc. - Common Stock is 2.69B
How many shares of Akero Therapeutics, Inc. - Common Stock are outstanding?
Akero Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.